Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ARTICLE
Year: 2013   |   Volume: 2   |   Issue: 4   |   Page: 275-280     View issue

The role of Trastuzumab Emtansine as a novel-targeted therapy for HER2+ breast cancer: A systematic review


Nikki Bajaj, Hamid Shaaban, Gunwant Guron, Michael Maroules
Abstract

Trastuzumab is the first humanized monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2), tyrosine kinase receptor, that has displayed excellent clinical activity in HER2-overexpressing breast cancer. Despite this, the majority of patients with metastatic HER2-positive breast cancer who initially demonstrate good clinical responses to trastuzumab within the first year of initiation of treatment start to develop resistance within 1 year of initiation of treatment. Even patients on trastuzumab-based chemotherapy regimens have been shown to progress within 1 year of therapy. The antibody-drug conjugate trastuzumab-DM1 (T-DM1) was designed to combine the biological activity of trastuzumab with the targeted delivery of a highly potent antimicrotubule agent, DM1 (N-methyl-N-[3-mercapto-1-oxopropyl]-l-alanine ester of maytansinol), a maytansine derivative, to HER2-positive breast cancer cells. Phase I and II clinical trials of T-DM1 as a single agent and in combination with paclitaxel, docetaxel, and pertuzumab have shown clinical activity and a favorable safety profile in HER2-positive metastatic breast cancer patients. The EMILIA study, a randomized phase III trial, has shown that T-DM1 provided objective tumor responses and significantly improved progression free survival and overall survival compared to lapatinib and capecitabine combination in HER2-positive metastatic breast cancer patients treated with a prior taxane and trastuzumab regimen. Based on these results, T-DM1 has been indicated in the management of patients with advanced and early stage HER2-positive breast cancer. In this review, we summarize evidence from clinical studies and aim to discuss the potential clinical and therapeutic implications of T-DM1 therapy in the management of HER2-positive breast cancer.

Cite this article
Vancouver
Bajaj N, Shaaban H, Guron G, Maroules M. The role of Trastuzumab Emtansine as a novel-targeted therapy for HER2+ breast cancer: A systematic review. Clin Cancer Investig J. 2013;2(4):275-80. https://doi.org/10.4103/2278-0513.121514
APA
Bajaj, N., Shaaban, H., Guron, G., & Maroules, M. (2013). The role of Trastuzumab Emtansine as a novel-targeted therapy for HER2+ breast cancer: A systematic review. Clinical Cancer Investigation Journal, 2(4), 275-280. https://doi.org/10.4103/2278-0513.121514

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Polaris Publication
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513